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Aims The COLchicine Cardiovascular Outcomes Trial (COLCOT) demonstrated the benefits of targeting inflammation
after myocardial infarction (MI). We aimed to determine whether time-to-treatment initiation (TTI) influences the




In COLCOT, patients were randomly assigned to receive colchicine or placebo within 30 days post-MI. Time-to-
treatment initiation was defined as the length of time between the index MI and the initiation of study medication.
The primary efficacy endpoint was a composite of cardiovascular death, resuscitated cardiac arrest, MI, stroke, or
urgent hospitalization for angina requiring coronary revascularization. The relationship between endpoints and vari-
ous TTI (<3, 4–7 and >8 days) was examined using multivariable Cox regression models. Amongst the 4661
patients included in this analysis, there were 1193, 720, and 2748 patients, respectively, in the three TTI strata.
After a median follow-up of 22.7 months, there was a significant reduction in the incidence of the primary endpoint
for patients in whom colchicine was initiated < Day 3 compared with placebo [hazard ratios (HR) = 0.52, 95% con-
fidence intervals (CI) 0.32–0.84], in contrast to patients in whom colchicine was initiated between Days 4 and 7
(HR = 0.96, 95% CI 0.53–1.75) or > Day 8 (HR = 0.82, 95% CI 0.61–1.11). The beneficial effects of early initiation
of colchicine were also demonstrated for urgent hospitalization for angina requiring revascularization (HR = 0.35),
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all coronary revascularization (HR = 0.63), and the composite of cardiovascular death, resuscitated cardiac arrest,
MI, or stroke (HR = 0.55, all P < 0.05).
...................................................................................................................................................................................................




COLCOT ClinicalTrials.gov number, NCT02551094.
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Introduction
Myocardial infarction (MI) is associated with an acute exacerbation
of cardiovascular (CV) inflammation superimposed on the chronic
atherosclerosis-related inflammatory process.1 Intense inflamma-
tion observed at the time of an acute MI has been shown to be
involved in the pathogenesis of post-infarction remodelling, with
NLRP3 inflammasome activation playing a particularly important
and deleterious role in this setting.2–5 Colchicine is an inexpensive,
orally administered, potent anti-inflammatory medication that was
initially extracted from the plant autumn crocus. Its mechanism of
action is through the inhibition of tubulin polymerization leading
to effects on cellular adhesion molecules, inflammatory chemo-
kines, and the inflammasome.6–8 Colchicine at the low dose of
0.5 mg daily was shown to significantly reduce the risk of ischae-
mic CV events by 23% compared with placebo when initiated
within the first 30 days after MI in the COLchicine Cardiovascular
Outcomes Trial (COLCOT).9
Whether the timing of inflammation reduction after MI has a clinic-
al impact is not known. Specifically, the importance of initiating colchi-
cine immediately during the hospitalization for MI remains to be
determined. We hypothesized that early initiation of inflammation re-
duction with colchicine is associated with greater clinical benefits
after MI. Therefore, we aimed to determine whether TTI of colchi-
cine influenced its beneficial impact on CV outcomes in COLCOT.
Methods
Study design and patient population
COLCOT was an international multicentre, randomized, double-blinded
trial that randomly assigned patients to receive either low-dose colchicine
Graphical Abstract
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(0.5 mg once daily) or placebo. The study protocol and main results have
been published.9 Patients were considered eligible if they had a recent MI
(<30 days). Main exclusion criteria were severe heart failure, reduced left
ventricular ejection fraction (<35%), recent stroke (<3 months), type 2
MI, recent (<3 years), or planned coronary artery bypass graft (CABG),
history of cancer (<3 years), and inflammatory bowel disease or chronic
diarrhoea. All patients enrolled in the trial benefitted from percutaneous
coronary intervention whenever indicated and guidelines-directed man-
agement of CV disease prior to randomization.9 Clinical follow-up con-
sisted of evaluations at 1 and 3 months after randomization and every
3 months thereafter. An independent clinical endpoint committee,
blinded to trial-group assignment, adjudicated clinical endpoints. The trial
was locally approved by the various institutional review boards, and all
patients signed a written informed consent before enrolment.9
Efficacy endpoints
The primary efficacy endpoint was a composite of CV death, resuscitated
cardiac arrest, MI, stroke, or urgent hospitalization for angina requiring
coronary revascularization. The secondary endpoints consisted of the
components of the primary efficacy endpoint, all-cause death, and a com-
posite of CV death, resuscitated cardiac arrest, MI, or stroke.9
Exploratory endpoints included all coronary revascularizations, including
both elective and urgent coronary revascularizations.9
Cut-offs for time-to-treatment initiation of
colchicine
Three different cut-offs for TTI were used in order to determine the as-
sociation between early initiation of therapy and clinical outcomes. These
cut-offs were determined based on the usual journey of patients with
MI.10,11 The first 30-day post-MI timeline was divided into three inde-
pendent periods of time and analysed as such: from Day 0 to 3, referring
to in-hospital management; from Day 4 to 7, referring to early post-
discharge period, and from Day 8 to 30, referring to late post-discharge
period.
Statistical analysis
Data were centrally analysed by an independent academic biostatistics
centre at the Montreal Health Innovations Coordinating Center.9 The
present analysis was conducted amongst patients who received at least
one dose of the study medication (referred to as the safety population in
the main protocol,9 Figure 1). Time-to-treatment initiation was defined as
the length of time in days between the index MI and the initiation of the
study medication, and three specific cut-offs were analysed (<_ Day 3,
Days 4 to 7, and >_ Day 8). Early initiation of therapy was defined as TTI
<_3 days. Baseline characteristics were summarized using counts and per-
centages for categorical variables and mean ± standard deviation (SD) for
continuous variables. For each baseline characteristic, comparisons were
made using ANOVA for continuous variables and Chi-Square test for cat-
egorical variables according to TTI strata. Analyses of the efficacy end-
points, expressed as time to event, were conducted according to TTI.
Adjusted hazard ratios (HR) along with 95% confidence intervals (CI)
were calculated from stepwise multivariable Cox regression models
adjusted for the same covariates that were used in the main analysis of
the COLCOT trial.9 All statistical tests were two-sided and conducted at
the 0.05 significance level. Statistical analyses were performed with the
use of SAS software, version 9.4 (SAS Institute).
Results
Baseline characteristics
Of the 4745 patients randomized in COLCOT, 4661 were included
in the present analysis (colchicine, N = 2322; placebo, N = 2339)
(Figure 1). Overall, patients were randomized at 13.5± 10.1 days fol-
lowing the index MI, 25.6% between Days 0 and 3, 15.4% between
Days 4 and 7 and 59.0% at Day 8 or after. Baseline characteristics
were similar between the colchicine and placebo groups (Table 1).
Patients were mostly men (81.0%) with a mean age of 60.5 years,
20.2% had diabetes, 51.0% had a history of hypertension, 29.7% were
active smokers, and 16.8% had had a prior percutaneous coronary
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Figure 1 Subject disposition, flow chart diagram.
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anti-platelet agent and a statin in 98.8%, 98.0%, and 99.0% of patients,
respectively. The vast majority of patients (93.0%) underwent PCI
during the index hospitalization, with no difference in terms of time
to PCI between the two groups.
Baseline characteristics according to TTI strata are shown in
Table 2. Patients in whom therapy was initiated between Days 0 and
3, when compared with those at Days 8–30, were younger
(59.1± 10.8 vs. 61.3± 10.4 years) and more often active smokers
(43.8% vs. 20.2%), had less commonly hypertension (41.1% vs.
56.2%), and diabetes (17.4% vs. 22.0%) but underwent more often
PCI associated with the index MI (95.8% vs. 91.3%), all P < 0.05.
Effects of time-to-treatment initiation on
the primary efficacy endpoint
The effects of colchicine on the primary endpoint according to TTI
are shown in Table 3 and Figure 2. A primary endpoint event occurred
in 4.3% of patients in the colchicine group, as compared with 8.3% of
those in the placebo group when TTI was between Days 0 and 3
(N = 1193, HR = 0.52, 95% CI 0.32–0.84, P = 0.007, Figure 3A).
Corresponding rates were 6.0% and 5.9% when TTI was between
Days 4 and 7 (N = 720) and 5.7% and 7.1% when TTI was on Day 8
or after (N = 2748), but these differences between groups did not
reach statistical significance. Table 3 also shows the percentages of
patients with events and the hazard ratios for the components of the
primary endpoint, including CV death (HR = 1.04, 95% CI 0.15–7.37),
resuscitated cardiac arrest (HR = 0.33, 95% CI 0.03–3.20), MI
(HR = 0.58, 95% CI 0.32–1.05), stroke (HR = 0.21, 95% CI 0.02–
1.81), and urgent hospitalization for angina requiring coronary revas-
cularization (HR = 0.35, 95% CI 0.14–0.88).
Effects of time-to-treatment initiation on
the secondary and exploratory efficacy
endpoints
The effects of colchicine on the secondary and exploratory endpoints
are shown in Table 3. The secondary efficacy endpoint consisting of a
composite of CV death, cardiac arrest, MI, or stroke occurred in
3.3% of the patients in the colchicine group and in 6.1% of those in
the placebo group when TTI was between Days 0 and 3 (HR = 0.55;
95% CI, 0.32–0.95, Figure 3B). The exploratory endpoint of all coron-
ary revascularizations occurred in 5.5% of patients in the colchicine
....................................................................................................................................................................................................................
Table 1 Baseline characteristics according to treatment allocation
Characteristics All patients Colchicine group Placebo group
(N 5 4661) (N 5 2322) (N 5 2339)
Age (years), mean ± SD 60.5 ± 10.6 60.6 ± 10.6 60.5 ± 10.6
Male sex, no. (%) 3774 (81.0%) 1861 (80.1%) 1913 (81.8%)
BMI (kg/m2), mean ± SD 28.3 ± 4.7 28.2 ± 4.8 28.4 ± 4.7
Current smoking, no./total no. (%) 1382/4659 (29.7) 694/2322 (29.9%) 688/2337 (29.4%)
History of hypertension, no. (%) 2377 (51.0) 1160 (50.0) 1217 (52.0)
History of diabetes, no. (%) 942 (20.2) 451 (19.4) 491 (21.0)
Prior MI, no. (%) 751 (16.1) 360 (15.5) 391 (16.7)
Prior PCI, no. (%) 783 (16.8) 382 (16.5) 401 (17.1)
Prior CABG, no. (%) 146 (3.1) 66 (2.8) 80 (3.4)
Prior HF, no. (%) 90 (1.9) 48 (2.1) 42 (1.8)
Prior stroke or TIA, no. (%) 119 (2.6) 53 (2.3) 66 (2.8)
PCI associated with the index event, no. (%) 4336 (93.0) 2154 (92.8) 2182 (93.3)
Medication use, no. (%):
Aspirin 4605 (98.8) 2291 (98.7) 2314 (98.9)
Other anti-platelet agent 4567 (98.0) 2267 (97.6) 2300 (98.3)
Statin 4615 (99.0) 2297 (98.9) 2318 (99.1)
Beta-blocker 4143 (88.9) 2077 (89.4) 2066 (88.3)
TTI 0–3 days, no. (%) 1193 (25.6) 604 (26.0) 589 (25.2)
TTI 4–7 days, no. (%) 720 (15.4) 364 (15.7) 356 (15.2)
TTT >_8 days, no. (%) 2748 (59.0) 1354 (58.3) 1394 (59.6)
Time from index MI to randomization (days),
mean ± SD
13.5 ± 10.1 13.5 ± 10.1 13.5 ± 10.0
Time from Index MI to PCI (days), mean ± SD 1.4 ± 2.9 1.4 ± 2.9 1.4 ± 2.9
Time from PCI to randomization (days), mean ±
SD
11.9 ± 9.9 11.9 ± 9.9 11.9 ± 9.9
Data were missing on the following characteristics: age (assessed according to date of birth; see below) for 431 patients (213 in the colchicine group and 218 in the placebo
group) and body-mass index (the weight in kilograms divided by the square of the height in meters) for 5 (1 and 4 patients, respectively).
Date of birth was not required field because it was considered in some countries to be sensitive data that could allow for the identification of patients.
For statistical reporting, missing information regarding the day of birth was replaced by 15, and missing information regarding the month and day of birth was replaced by 1 July.
CABG, coronary artery bypass graft surgery; HF, heart failure; PCI, percutaneous coronary intervention; TIA, transient ischaemic attack.
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..group, as compared with 8.7% of those in the placebo group when
TTI was between Days 0 and 3 (HR = 0.63, 95% CI 0.40–0.97). There
were six deaths in both study groups when TTI was between Days 0
and 3 (HR = 1.03, 95% 0.33–3.19).
Discussion
This analysis of COLCOT shows that early initiation of low-dose col-
chicine within the first 3 days after MI is associated with a reduction
of 48% in the risk of the primary endpoint consisting of a composite
of CV death, resuscitated cardiac arrest, MI, stroke, or urgent hospi-
talization for angina requiring coronary revascularization, in compari-
son with placebo. This result was due to a lower incidence of MIs,
strokes, and urgent hospitalizations for angina leading to coronary
revascularization. The secondary efficacy endpoint consisting of a
composite of CV death, resuscitated cardiac arrest, MI, or stroke was
also significantly reduced by 45% with early initiation of low-dose col-
chicine. The benefits were more marked when treatment was initi-
ated within the first 3 days after MI, as compared with between Days
4 and 30, supporting the strategy of in-hospital initiation of colchicine
in order to improve CV outcomes post-MI.
Acute inflammatory response following
myocardial infarction
Convincing evidence converge towards inflammation as a key factor
in CV disease progression and exacerbation.12 In the acute phase of
MI, cardiomyocyte necrosis generates damage-associated molecular
patterns, which in turn activate the complement cascade and stimu-
late toll-like receptor and interleukin-1 signalling.13,14 These factors
trigger an intense inflammatory response that may lead to adverse
myocardial remodelling4 and in which activated inflammasomes with-
in myocardial fibroblasts play a crucial role.2,3,5 Furthermore, an acute
systemic inflammation response has been demonstrated in patients
with recent MI15,16 and associated with infarct size.17 Colchicine binds
to tubulin and prevents microtubule polymerization, consequently
reducing inflammasome activation and pro-inflammatory cytokine re-
lease. Colchicine concentrates preferentially in white blood cells,
thus exerting its anti-inflammatory effects even at low doses.18 The
importance of early initiation of colchicine on CV outcomes after MI
in COLCOT is compatible with an effect on innate immune cells.17
Short-term anti-inflammatory therapy with colchicine was also asso-
ciated with smaller infarct size and reduced inflammatory response in
a pilot study of patients with STEMI undergoing primary PCI.19
....................................................................................................................................................................................................................
Table 2 Baseline characteristics according to time-to-treatment initiation
Characteristics TTI 0–3 days TTI 4–7 days TTT  8 days Pa Pb
(N 5 1193) (N 5 720) (N 5 2748)
Age (years), mean ± SD 59.1 ± 10.8 60.1 ± 11.0 61.3 ± 10.4 <0.0001 <0.0001
Male sex, no. (%) 980 (82.2) 605 (84.0) 2189 (80.0) 0.014 0.071
BMI (kg/m2), mean ± SD 28.1 ± 4.6 27.7 ± 4.6 28.6 ± 4.8 <0.0001 0.004
Current smoking, no. (%) 522 (43.8) 306 (42.6) 554 (20.2) <0.0001 <0.0001
History of hypertension, no. (%) 490 (41.1) 343 (47.6) 1544 (56.2) <0.0001 <0.0001
History of diabetes, no. (%) 208 (17.4) 130 (18.1) 604 (22.0) 0.001 0.001
Prior MI, no. (%) 170 (14.3) 111 (15.4) 470 (17.1) 0.070 —
Prior PCI, no. (%) 182 (15.3) 107 (14.9) 494 (18.0) 0.035 0.037
Prior CABG, no. (%) 34 (2.9) 30 (4.2) 82 (3.0) 0.218 —
Prior HF, no. (%) 14 (1.2) 12 (1.7) 64 (2.3) 0.046 0.017
Prior stroke or TIA, no. (%) 20 (1.7) 21 (2.9) 78 (2.8) 0.084 —
PCI associated with the index event, no. (%) 1143 (95.8) 685 (95.1) 2508 (91.3) <0.0001 <0.0001
Medication use, no. (%)
Aspirin 1181 (99.0) 715 (99.3) 2709 (98.6) 0.219 —
Other anti-platelet agent 1177 (98.7) 708 (98.3) 2682 (97.6) 0.072 —
Statin 1188 (99.6) 708 (98.3) 2719 (98.9) 0.024 0.047
Beta-blocker 1093 (91.6) 642 (89.2) 2408 (87.6) 0.001 0.0003
Time from index MI to randomization (days),
mean ± SD
2.1 ± 0.8 5.1 ± 1.1 20.8 ± 6.6 —
Time from index MI to PCI (days), mean ± SD 0.4 ± 0.7 1.4 ± 1.8 1.8 ± 3.6 <0.0001 <0.0001
Time from PCI to randomization (days), mean ±
SD
1.6 ± 0.9 3.7 ± 1.9 18.8 ± 7.3 <0.0001 <0.001
Data were missing on the following characteristics: age (assessed according to date of birth; see below) for 431 patients (213 in the colchicine group and 218 in the placebo
group) and body-mass index (the weight in kilograms divided by the square of the height in meters) for 5 (1 and 4 patients, respectively).
Date of birth was not a required field because it was considered in some countries to be sensitive data that could allow for the identification of patients. For statistical reporting,
missing information regarding the day of birth was replaced by 15, and missing information regarding the month and day of birth was replaced by 1 July.
CABG, coronary artery bypass graft surgery; HF, heart failure; PCI, percutaneous coronary intervention; TIA, transient ischaemic attack.
aGroup comparison TTI 0–3 vs. TTI 4–7 vs. TTI >_ 8 days.
bGroup comparison TTI 0–3 vs. TTI >_ 8 days.
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. The benefit of colchicine in reducing the risk of stroke was large in
COLCOT, which supports the favourable vascular effects of inflam-
mation reduction with this medication. Whether there is a particular
effect of colchicine on the cerebral vascular bed is unknown. In con-
trast, there was no significant impact of colchicine on the incidence of
atrial fibrillation in COLCOT.
Targeting residual cardiovascular risk
with anti-inflammatory therapy
Inflammation contributes to all phases of atherosclerotic disease, and
recent data from randomized trials have provided novels insights into
the role of inflammation modulation for CV risk reduction.20 The
Canakinumab Anti-Inflammatory Thrombosis Outcomes Study
(CANTOS) of patients with stable coronary disease demonstrated
that the selective IL-1 b inhibitor canakinumab yielded a reduction of
15% in the risk of a CV event,21 which was correlated with the lower-
ing of inflammation biomarker levels.22 The main COLCOT results
revealed that colchicine reduced the risk of ischaemic CV events by
23% in the post-MI setting.9 Results from the present COLCOT ana-
lysis suggest that early suppression of inflammation after MI provides
....................................................................................................................................................................................................................
Table 3 Efficacy endpoints according to time-to-treatment initiation (N 5 4661, colchicine vs. placebo)
Endpoints TTI 0–3 days, N 5 1193 TTI 4–7 days, N 5 720 TTI  8 days, N 5 2748
Colchicine vs. placebo, no. (%) Colchicine vs. placebo, no. (%) Colchicine vs. placebo, no. (%)
HR (95% CI); P HR (95% CI); P HR (95% CI); P
Primary composite endpoint 26 (4.3%) vs. 49 (8.3%) 22 (6.0%) vs. 21 (5.9%) 77 (5.7%) vs. 99 (7.1%)
0.52 (0.32–0.84); P = 0.007 0.96 (0.53–1.75); P = 0.896 0.82 (0.61–1.11); P = 0.200
CV death 2 (0.3%) vs. 2 (0.3%) 2 (0.5%) vs. 4 (1.1%) 15 (1.1%) vs. 18 (1.3%)
1.04 (0.15–7.37); P = 0.970 0.45 (0.08–2.46); P = 0.356 0.89 (0.45–1.76); P = 0.734
Resuscitated cardiac arrest 1 (0.2%) vs. 3 (0.5%) 2 (0.5%) vs. 1 (0.3%) 2 (0.1%) vs. 2 (0.1%)
0.33 (0.03–3.20); P = 0.340 1.90 (0.17–20.95); P = 0.600 1.02 (0.14–7.22); P = 0.986
MI 17 (2.8%) vs. 29 (4.9%) 16 (4.4%) vs. 9 (2.5%) 52 (3.8%) vs. 59 (4.2%)
0.58 (0.32–1.05); P = 0.071 1.67 (0.74–3.78); P = 0.218 0.93 (0.64–1.35); P = 0.710
Stroke 1 (0.2%) vs. 5 (0.8%) 1 (0.3%) vs. 3 (0.8%) 2 (0.1%) vs. 11 (0.8%)
0.21 (0.02–1.81); P = 0.156 0.28 (0.03–2.71); P = 0.272 0.19 (0.04–0.84); P = 0.029
Urgent hospitalization for angina
requiring coronary
revascularization
6 (1.0%) vs. 17 (2.9%) 4 (1.1%) vs. 6 (1.7%) 15 (1.1%) vs. 26 (1.9%)
0.35 (0.14–0.88); P = 0.026 0.63 (0.18–2.24); P = 0.476 0.61 (0.32–1.16); P = 0.131
Secondary composite endpoint 20 (3.3%) vs. 36 (6.1%) 18 (4.9%) vs. 16 (4.5%) 67 (4.9%) vs. 77 (5.5%)
0.55 (0.32–0.95); P = 0.031 1.04 (0.53–2.03); P = 0.919 0.92 (0.66–1.28); P = 0.629
All-cause death 6 (1.0%) vs. 6 (1.0%) 8 (2.2%) vs. 7 (2.0%) 26 (1.9%) vs. 31 (2.2%)
1.03 (0.33–3.19); P = 0.962 1.03 (0.37–2.84); P = 0.957 0.90 (0.53–1.51); P = 0.684
All coronary revascularizations 33 (5.5%) vs. 51 (8.7%) 25 (6.9%) vs. 18 (5.1%) 72 (5.3%) vs. 94 (6.7%)
0.63 (0.40–0.97); P = 0.037 1.41 (0.76–2.61); P = 0.275 0.81 (0.59–1.10); P = 0.172
The primary composite endpoint included CV death, resuscitated cardiac arrest, MI, stroke, or urgent hospitalization for angina requiring coronary revascularization. The sec-
ondary composite endpoint included CV death, resuscitated cardiac arrest, MI, and stroke. Only the initial event was counted in the analyses of time to first event for the pri-
mary composite endpoint and for the secondary composite endpoint.
Covariates included in the stepwise multivariable Cox regression models are: age; sex; BMI; smoking status; history of diabetes; history of hypertension; history of dyslipidaemia;
prior MI; prior coronary revascularization (prior PCI or prior CABG); prior heart failure. All models also included TTI, group and the interaction between group and TTI.
CI, confidence interval; CV, cardiovascular; MI, myocardial infarction; HR, hazard ratio; PCI, percutaneous coronary intervention; TTI, time-to-treatment initiation.
Figure 2 Associations between time-to-treatment initiation and
the risk of occurrence of the primary composite endpoint. The
adjusted hazard ratio and 95% confidence intervals come from a
quadratic multivariable Cox regression model.
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..even greater benefits, with a reduction of 48% in the risk of the com-
posite primary endpoint when colchicine was initiated between Days
0 and 3. The demonstrated cost-effectiveness of low-dose colchicine
also supports its large-scale use after MI.23 Results of the LoDoCo224
study of patients with stable coronary artery disease will complement
those of COLCOT in the post-MI setting.
Limitations
This analysis has limitations. Time-to-treatment initiation was ana-
lysed using three strata chosen according to the usual journey of
patients with uncomplicated MI. A larger trial might have allowed a
better assessment of individual endpoints and subgroups.
Conclusions
Early initiation of low-dose colchicine after MI greatly reduced the
risk of ischaemic CV events compared with placebo. These results
support in-hospital initiation of adjunctive anti-inflammatory therapy
with colchicine for post-MI prevention.
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